Raymond James Financial Services Advisors Inc. Has $175,000 Stake in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)

Raymond James Financial Services Advisors Inc. increased its holdings in shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) by 10.7% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 15,330 shares of the biotechnology company’s stock after purchasing an additional 1,483 shares during the period. Raymond James Financial Services Advisors Inc.’s holdings in Ironwood Pharmaceuticals were worth $175,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in IRWD. SG Americas Securities LLC acquired a new stake in Ironwood Pharmaceuticals in the 3rd quarter worth $1,818,000. Exchange Traded Concepts LLC increased its stake in Ironwood Pharmaceuticals by 46.5% during the third quarter. Exchange Traded Concepts LLC now owns 235,690 shares of the biotechnology company’s stock valued at $2,270,000 after acquiring an additional 74,758 shares during the period. Xponance Inc. acquired a new position in Ironwood Pharmaceuticals in the 3rd quarter valued at approximately $144,000. GW Henssler & Associates Ltd. bought a new stake in shares of Ironwood Pharmaceuticals in the 3rd quarter worth approximately $186,000. Finally, Mackenzie Financial Corp grew its holdings in shares of Ironwood Pharmaceuticals by 21.5% during the 3rd quarter. Mackenzie Financial Corp now owns 12,713 shares of the biotechnology company’s stock worth $123,000 after purchasing an additional 2,253 shares in the last quarter.

Ironwood Pharmaceuticals Price Performance

Shares of Ironwood Pharmaceuticals stock opened at $8.08 on Friday. The firm has a 50 day simple moving average of $9.64 and a 200 day simple moving average of $10.66. Ironwood Pharmaceuticals, Inc. has a fifty-two week low of $7.53 and a fifty-two week high of $15.70. The firm has a market cap of $1.26 billion, a P/E ratio of -1.24 and a beta of 0.55.

Analyst Ratings Changes

Several research analysts recently commented on IRWD shares. Piper Sandler raised their target price on Ironwood Pharmaceuticals from $20.00 to $21.00 and gave the stock an “overweight” rating in a research report on Friday, February 16th. StockNews.com lowered shares of Ironwood Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, April 6th. Craig Hallum initiated coverage on shares of Ironwood Pharmaceuticals in a research note on Wednesday, January 17th. They issued a “buy” rating and a $21.00 target price on the stock. Finally, Wells Fargo & Company reduced their price target on shares of Ironwood Pharmaceuticals from $20.00 to $14.00 and set an “overweight” rating on the stock in a research report on Friday, March 1st. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $19.80.

Insider Activity

In other news, Director Jon R. Duane purchased 6,920 shares of the business’s stock in a transaction dated Wednesday, March 6th. The shares were acquired at an average price of $8.70 per share, with a total value of $60,204.00. Following the completion of the purchase, the director now directly owns 121,028 shares of the company’s stock, valued at approximately $1,052,943.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, insider Minardo John sold 47,380 shares of the stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $15.24, for a total value of $722,071.20. Following the sale, the insider now directly owns 224,796 shares in the company, valued at approximately $3,425,891.04. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Jon R. Duane bought 6,920 shares of the business’s stock in a transaction on Wednesday, March 6th. The stock was purchased at an average price of $8.70 per share, for a total transaction of $60,204.00. Following the completion of the acquisition, the director now owns 121,028 shares of the company’s stock, valued at approximately $1,052,943.60. The disclosure for this purchase can be found here. In the last ninety days, insiders sold 273,008 shares of company stock valued at $4,160,642. Company insiders own 13.10% of the company’s stock.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.